Information Provided By: 
Fly News Breaks for August 16, 2018
GSK, RHHBY, NVS, AZN
Aug 16, 2018 | 08:24 EDT
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
News For AZN;NVS;RHHBY;GSK From the Last 2 Days
RHHBY
Apr 26, 2024 | 11:59 EDT
AZN
Apr 26, 2024 | 11:59 EDT
AZN
Apr 26, 2024 | 11:37 EDT
RHHBY
Apr 25, 2024 | 11:44 EDT
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
